Innocan Pharma Reports Q3 2023 Results

HERZLIYA, Israel, and CALGARY, Alberta — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and nine months period ended September 30, 2023.

“We are thrilled with the significant growth we achieved in the third quarter,” says Iris Bincovich, CEO of Innocan. “Our strategic focus on the midterm-goal of FDA approvals for our LPT-CBD-loaded liposome platform, alongside the robust sales from our subsidiary, B.I. Sky Global Ltd., have significantly contributed to this increase in both revenue and gross profit. We remain committed to our vision and are optimistic about the future.”

Financial highlights for the third quarter of 2023

  • Revenue: The Company posted US$4.083M in revenue for the three months ended September 30, 2023, marking an increase of US$3.334M compared to the three months ended September 30, 2022. This surge in revenue is primarily attributable to the robust sales performance of Innocan’s subsidiary, B.I. Sky Global Ltd.
  • Gross Profit: For the three months ended September 30, 2023, the Company reported a gross profit of US$3.664M, compared to US$715,000 for the three months ended September 30, 2022, representing an increase of US$2.949M.
  • Cash Balance: As of September 30, 2023, the Company’s cash balance was US$4.024M.

For a comprehensive understanding of Innocan’s consolidated financial statements and related management’s discussion and analysis for the three and nine months period ended September 30, 2023, please visit the Company’s profile at www.sedarplus.ca.

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Chronic Pain Management and Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti-inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company’s products, requisite regulatory approvals and the timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.



Comments

Post a Comment

Popular posts from this blog

8 Breeders and Seed Banks with Desirable Strains for 2024

Every cannabis grower hopes to have a plentiful harvest full of top-shelf buds. One of the best ways to meet that goal is by planting quality genetics . But with so many breeders out there, it may be difficult to determine the best cannabis seed banks for your needs. Cannabis seeds are technically legal across the United States since they contain less than 0.3 percent THC, according to the 2018 Farm Bill. In the last six years, dozens of online seed banks have popped up vying for market share. Offering feminized cannabis seeds and autoflowering seeds in many of the most popular strains , there are endless genetics from which to choose. The best cannabis seeds for an operator may vary depending on whether a grow is indoors or outdoors, their preferred growing medium, and the ultimate goal for the crop. For example, are you hoping to extract rosin or sell smokable buds? These questions must be considered prior to selecting marijuana strains and, by proxy, a source for those genetics....
Read more

Audacious Awarded New Jersey Adult Use Licenses

LAS VEGAS – Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) “AUSA”, “AUDACIOUS”, or the “Company), today announced the Company was awarded a provisional Cultivation license, as well as a provisional Manufacturing license in the state of New Jersey. With a population close to 9 million people, New Jersey officially announced on Thursday that adult-use marijuana sales will start on April 21. Residents in the Garden State voted to legalize recreational cannabis in 2020. Market insiders estimate the total New Jersey opportunity to approach U.S.$2 billion[1]. To date, the state has awarded 37 conditional cultivation licenses and 70 conditional manufacturing licenses, in addition to allowing 6 of the incumbent 12 medical use operators to participate. The limited number of licenses awarded and the limited availability of municipalities that have opted in provides AUDACIOUS with a significant early mover advantage. Terry Booth, CEO, commented, “AUDACIOUS’ new team, just o...
Read more

Will This Be Our Year?

In 1919, a ban on alcohol exposed a cultural divide between urban and rural America and led to a spike in organized crime. Federal, state, and local governments struggled to adapt to the abrupt change in reality that came to be known as Prohibition. The task of enforcing new regulations initially fell to the Internal Revenue Service (thus the term “revenuers” for federal agents who hunted moonshiners) before being passed to the Department of Justice (DOJ). While enforcement was concentrated in rural areas and small towns—where some folks made decent livings by operating homemade stills—urban dwellers continued to enjoy alcohol courtesy of bootleggers and speakeasies. With the end of Prohibition in 1933, after the broken bottles, blood, and dust finally settled, an article in The United States News (now U.S. News & World Report) attempted to give the citizenry an idea of how the path forward might look. The open season for liquor-control laws is at hand. With repeal on December ...
Read more